Royston P - Search Results

1

Oza B, Eisen T, Stewart GD, Bex A, Royston P, Meade A; authors on the SORCE TMG. Oza B, et al. Among authors: royston p. J Clin Oncol. 2023 Jan 20;41(3):704-706. doi: 10.1200/JCO.22.01124. Epub 2022 Sep 27. J Clin Oncol. 2023. PMID: 36166721 No abstract available.

2

External Validation of the 2003 Leibovich Prognostic Score in Patients Randomly Assigned to SORCE, an International Phase III Trial of Adjuvant Sorafenib in Renal Cell Cancer.

Oza B, Eisen T, Frangou E, Stewart GD, Bex A, Ritchie AWS, Kaplan R, Smith B, Davis ID, Stockler MR, Albiges L, Escudier B, Larkin J, Joniau S, Hancock B, Hermann GG, Bellmunt J, Parmar MKB, Royston P, Meade A. Oza B, et al. Among authors: royston p. J Clin Oncol. 2022 Jun 1;40(16):1772-1782. doi: 10.1200/JCO.21.01090. Epub 2022 Feb 25. J Clin Oncol. 2022. PMID: 35213214 Free PMC article. Clinical Trial.

3

Prognostic model for survival in patients with metastatic renal cell carcinoma: results from the international kidney cancer working group.

Manola J, Royston P, Elson P, McCormack JB, Mazumdar M, Négrier S, Escudier B, Eisen T, Dutcher J, Atkins M, Heng DY, Choueiri TK, Motzer R, Bukowski R; International Kidney Cancer Working Group. Manola J, et al. Among authors: royston p. Clin Cancer Res. 2011 Aug 15;17(16):5443-50. doi: 10.1158/1078-0432.CCR-11-0553. Epub 2011 Aug 9. Clin Cancer Res. 2011. PMID: 21828239 Free PMC article.

4

Prognostic factors for renal cell carcinoma.

Furniss D, Harnden P, Ali N, Royston P, Eisen T, Oliver RT, Hancock BW; National Cancer Research Institute Renal Clinical Studies Group. Furniss D, et al. Among authors: royston p. Cancer Treat Rev. 2008 Aug;34(5):407-26. doi: 10.1016/j.ctrv.2007.12.008. Epub 2008 Apr 28. Cancer Treat Rev. 2008. PMID: 18440705 Review.

5

Flexible parametric proportional-hazards and proportional-odds models for censored survival data, with application to prognostic modelling and estimation of treatment effects.

Royston P, Parmar MK. Royston P, et al. Stat Med. 2002 Aug 15;21(15):2175-97. doi: 10.1002/sim.1203. Stat Med. 2002. PMID: 12210632

6

Construction and validation of a prognostic model across several studies, with an application in superficial bladder cancer.

Royston P, Parmar MK, Sylvester R. Royston P, et al. Stat Med. 2004 Mar 30;23(6):907-26. doi: 10.1002/sim.1691. Stat Med. 2004. PMID: 15027080

7

Visualizing length of survival in time-to-event studies: a complement to Kaplan-Meier plots.

Royston P, Parmar MK, Altman DG. Royston P, et al. J Natl Cancer Inst. 2008 Jan 16;100(2):92-7. doi: 10.1093/jnci/djm265. Epub 2008 Jan 8. J Natl Cancer Inst. 2008. PMID: 18182621 Clinical Trial.

8

The use of restricted mean survival time to estimate the treatment effect in randomized clinical trials when the proportional hazards assumption is in doubt.

Royston P, Parmar MK. Royston P, et al. Stat Med. 2011 Aug 30;30(19):2409-21. doi: 10.1002/sim.4274. Epub 2011 May 25. Stat Med. 2011. PMID: 21611958

9

Meta-analysis of time-to-event outcomes from randomized trials using restricted mean survival time: application to individual participant data.

Wei Y, Royston P, Tierney JF, Parmar MK. Wei Y, et al. Among authors: royston p. Stat Med. 2015 Sep 20;34(21):2881-98. doi: 10.1002/sim.6556. Epub 2015 Jun 23. Stat Med. 2015. PMID: 26099573 Free PMC article.

10

Is treatment with interferon-alpha effective in all patients with metastatic renal carcinoma? A new approach to the investigation of interactions.

Royston P, Sauerbrei W, Ritchie A. Royston P, et al. Br J Cancer. 2004 Feb 23;90(4):794-9. doi: 10.1038/sj.bjc.6601622. Br J Cancer. 2004. PMID: 14970855 Free PMC article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

185 results

Search Page

Filters